{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:07:37Z","timestamp":1762247257446,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274305","82205052"],"award-info":[{"award-number":["82274305","82205052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22YF1449300"],"award-info":[{"award-number":["22YF1449300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2018ZX10302204","2014ZX10005001"],"award-info":[{"award-number":["2018ZX10302204","2014ZX10005001"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clinthera.2025.02.009","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T04:33:20Z","timestamp":1742704400000},"page":"e6-e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum Golgi Protein 73 as a Predictor of Virologic Response to Entecavir Antiviral Therapy in Patients with Chronic Hepatitis B and Liver Fibrosis: A Retrospective Study"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8871-341X","authenticated-orcid":false,"given":"Yangqing","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingzi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haina","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenghai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.02.009_bib0001","unstructured":"World Health Organization. (2021). Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016\u20132021: actions for impact. [EB\/OL]. https:\/\/www.who.int\/publications\/i\/item\/9789240027077."},{"issue":"2","key":"10.1016\/j.clinthera.2025.02.009_bib0002","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jhep.2022.10.006","article-title":"Corrigendum to 'EASL recommendations on treatment of hepatitis C: final update of the series' [J Hepatol 73 (2020) 1170-1218]","volume":"78","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.clinthera.2025.02.009_bib0003","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1053\/jhep.2002.32525","article-title":"Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease","volume":"35","author":"Kladney","year":"2002","journal-title":"Hepatology (Baltimore, Md.)"},{"issue":"6","key":"10.1016\/j.clinthera.2025.02.009_bib0004","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2005.05.028","article-title":"GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma","volume":"43","author":"Marrero","year":"2005","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.clinthera.2025.02.009_bib0005","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1136\/gut.2010.214916","article-title":"Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma","volume":"59","author":"Mao","year":"2010","journal-title":"Gut"},{"issue":"16\u201317","key":"10.1016\/j.clinthera.2025.02.009_bib0006","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.clinbiochem.2014.08.010","article-title":"Serum gp73 is also a biomarker for diagnosing cirrhosis in population with chronic HBV infection","volume":"47","author":"Qiao","year":"2014","journal-title":"Clin Biochem"},{"issue":"6","key":"10.1016\/j.clinthera.2025.02.009_bib0007","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/jmv.25045","article-title":"Predictive value of serum golgi protein 73 for prominent hepatic necroinflammation in chronic HBV infection","volume":"90","author":"Xu","year":"2018","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.clinthera.2025.02.009_bib0008","doi-asserted-by":"crossref","first-page":"e12538","DOI":"10.1111\/cpr.12538","article-title":"Golgi protein 73 and its diagnostic value in liver diseases","volume":"52","author":"Xia","year":"2019","journal-title":"Cell Proliferat"},{"issue":"12","key":"10.1016\/j.clinthera.2025.02.009_bib0009","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1002\/jmv.25718","article-title":"GP73 facilitates hepatitis B virus replication by repressing the NF-\u03bab signaling pathway","volume":"92","author":"Liu","year":"2020","journal-title":"J Med Virol"},{"issue":"4","key":"10.1016\/j.clinthera.2025.02.009_bib0010","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.clinthera.2025.02.009_bib0011","first-page":"1425","article-title":"Guidelines for the prevention and treatment of chronic Hepatitis B (version 2022)","volume":"11","author":"You","year":"2023","journal-title":"J Clin Translation Hepatol"},{"issue":"3","key":"10.1016\/j.clinthera.2025.02.009_bib0012","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jhep.2007.04.011","article-title":"Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients","volume":"47","author":"Buti","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2025.02.009_bib0013","doi-asserted-by":"crossref","unstructured":"Sonneveld, M. J., Park, J. Y., Kaewdech, A., et al. \u2026 CREATE Study Group (2022). Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE). Clin Gastroenterol Hepatol, 20(4), e784\u2013e793. https:\/\/doi.org\/10.1016\/j.cgh.2020.12.005","DOI":"10.1016\/j.cgh.2020.12.005"},{"key":"10.1016\/j.clinthera.2025.02.009_bib0014","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/aid2.13190","article-title":"Predictors of HBeAg loss after nucleos(t)ide analogues treatment for chronic hepatitis B: a preliminary finding","volume":"8","author":"Wen","year":"2021","journal-title":"Adv Dig Med"},{"issue":"4","key":"10.1016\/j.clinthera.2025.02.009_bib0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.14218\/JCTH.2023.00378","article-title":"The relationship between viral replication and the severity of hepatic necroinflammatory damage changed before HBeAg loss in patients with chronic Hepatitis B Virus infection","volume":"12","author":"Wang","year":"2024","journal-title":"J Clin Translation Hepatol"},{"issue":"4","key":"10.1016\/j.clinthera.2025.02.009_bib0016","first-page":"5264","article-title":"Hepatitis B virus upregulates GP73 expression by activating the HIF-2\u03b1 signaling pathway","volume":"15","author":"Yang","year":"2018","journal-title":"Oncol Letters"},{"issue":"3","key":"10.1016\/j.clinthera.2025.02.009_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006938","article-title":"Correction: GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation","volume":"14","author":"Zhang","year":"2018","journal-title":"PLoS pathogens"},{"issue":"4","key":"10.1016\/j.clinthera.2025.02.009_bib0018","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2020.11.003","article-title":"Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity","volume":"74","author":"Suslov","year":"2021","journal-title":"J Hepatol"},{"issue":"14","key":"10.1016\/j.clinthera.2025.02.009_bib0019","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.4103\/0366-6999.160488","article-title":"Baseline hepatitis B virus DNA level is a promising factor for predicting the 3 (rd) month virological response to entecavir therapy: a study of strict defined hepatitis B virus induced cirrhosis","volume":"128","author":"XU","year":"2015","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"10.1016\/j.clinthera.2025.02.009_bib0020","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/gutjnl-2020-321116","article-title":"Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation","volume":"70","author":"Seto","year":"2021","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.clinthera.2025.02.009_bib0021","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3855\/jidc.11447","article-title":"Mutations in reverse transcriptase region of HBV affect Hepatitis B surface antigen titers and its correlation with HBV DNA","volume":"13","author":"Shen","year":"2019","journal-title":"J Infect Dev Ctries"},{"issue":"5","key":"10.1016\/j.clinthera.2025.02.009_bib0022","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/jvh.13061","article-title":"Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA","volume":"26","author":"Chen","year":"2019","journal-title":"J Viral Hepatitis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825000712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:03:02Z","timestamp":1762246982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825000712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0149291825000712"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.02.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Golgi Protein 73 as a Predictor of Virologic Response to Entecavir Antiviral Therapy in Patients with Chronic Hepatitis B and Liver Fibrosis: A Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}